

---

## The Great Eight—2011 Annual Meeting Best Paper Presentations

**Monday, October 17**

**1:30 p.m.–3:30 p.m.**

**Convention Center: Rooms 315 & 316**

All Best Paper finalists will present their papers on Monday, October 17, from 1:30 p.m. to 3:30 p.m. during The Great Eight Platform Presentation. Finalists will also have posters displayed during the Scientific Poster Presentation sessions on October 17, October 18, and October 19. Presentation of the Best Paper Award will be on Tuesday, October 18, during the Scientific Poster Presentation, II session in Exhibit Hall A of the David L. Lawrence Convention Center.

*Moderator: Mary H.H. Ensom, Pharm.D., FCCP*

Professor and Director of the Doctor of Pharmacy Program, Faculty of Pharmaceutical Sciences and Distinguished University Scholar, University of British Columbia (UBC); Clinical Pharmacy Specialist, Children's & Women's Health Centre of British Columbia, Victoria, British Columbia, Canada

### **3F. Incidence, Characteristics, and Outcomes of Adverse Drug Events Resulting in Intensive Care Admission in Oncology Patients.**

*Lama H. Nazer, Pharm.D., BCPS, Feras I. Hawari, M.D., Rana A. Eljaber, Pharm.D.;* King Hussein Cancer Center, Amman, Jordan

### **102F. GFR Equations Overestimate Creatinine Clearance in Elderly Individuals Enrolled in the NIA-Baltimore Longitudinal Study on Aging (BLSA).**

*Thomas C. Dowling, Pharm.D., Ph.D.,<sup>1</sup> John D. Sorkin, M.D., Ph.D.,<sup>2</sup> Luigi Ferrucci, M.D., Ph.D.<sup>3</sup>;* (1)Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD; (2)Division of Gerontology, University of Maryland School of Medicine, Baltimore, MD; (3)Biomedical Research Center, National Institute on Aging, Baltimore, MD

### **158F. Pharmacokinetics and Pharmacodynamics of Meropenem in Morbidly Obese, Hospitalized Patients.**

*S. Christian Cheatham, Pharm.D.,<sup>1</sup> Megan R. Fleming, Pharm.D.,<sup>1</sup> Daniel P. Healy, Pharm.D.,<sup>2</sup> Christina E.K. Chung, Pharm.D.,<sup>3</sup> Michael B. Kays, Pharm.D.<sup>3</sup>;* (1)St. Francis Hospitals and Health Centers, Beech Grove, IN; (2)James Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH; (3)Purdue University College of Pharmacy, Indianapolis, IN

**160F. Efficacy and Safety of 6 Months of Low- vs. High-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-Risk Renal Transplant Recipients.**

*Steven Gabardi, Pharm.D., BCPS,<sup>1</sup> Lisa M. McDevitt, Pharm.D., BCPS,<sup>2</sup> Christin Rogers, Pharm.D.,<sup>3</sup> Eric Tichy, Pharm.D., BCPS,<sup>4</sup> Renee Weng, Pharm.D.,<sup>5</sup> Ruth-Ann M. Lee, Pharm.D.<sup>6</sup>;* (1)Department of Pharmacy and Renal Division, Brigham and Women's Hospital; Department of Medicine, Harvard Medical School, Boston, MA; (2)Tufts Medical Center, Boston, MA; (3)Beth Israel Deaconess Medical Center, Boston, MA; (4)Yale-New Haven Hospital, New Haven, CT; (5)UC-Irvine, Orange, CA; (6)Massachusetts General Hospital, Boston, MA

**220F. Endothelial Nitric Oxide Synthase Polymorphisms and Endothelial Function in Coronary Artery Disease Patients.**

*Savanna Steele, Pharm.D.,<sup>1</sup> Bryant Tran, Pharm.D., M.S.,<sup>1</sup> Kyle J. Ellis, Pharm.D.,<sup>1</sup> Almasa Bass, Pharm.D.,<sup>1</sup> Robert N. Schuck, Pharm.D.,<sup>1</sup> Melissa Caughey, RVT, MPH,<sup>2</sup> George A. Stouffer, M.D.,<sup>2</sup> Alan L. Hinderliter, M.D.,<sup>2</sup> Craig R. Lee, Pharm.D., Ph.D.<sup>1</sup>;* (1)Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; (2)Division of Cardiology; School of Medicine, University of North Carolina, Chapel Hill, NC

**223F. Exposure-Response Analysis of Eslicarbazepine Acetate Adjunctive Treatment of Patients with Partial-Onset Seizures.**

*Jahnvi Kharidia, Ph.D.,<sup>1</sup> Julie Passarell, M.A.,<sup>2</sup> Gary Maier, Ph.D.,<sup>1</sup> Jacqueline Zummo, M.S., MPH, MBA,<sup>1</sup> Elizabeth Ludwig, Pharm.D.,<sup>2</sup> Ted Grasela, Pharm.D., Ph.D.,<sup>2</sup> Jill Fiedler-Kelly, M.S.<sup>2</sup>;* (1)Sunovion Pharmaceuticals, Inc, Marlborough, MA; (2)Cognigen Corp, Buffalo, NY

**259F. Corticosteroid Withdrawal in Renal Transplant Recipients: An Analysis of the Mycophenolic Acid Observational Renal Transplant Registry.**

*Kimi Ueda Stevenson, Pharm.D., BCPS,<sup>1</sup> Anne Wiland, Pharm.D., BCPS,<sup>2</sup> V. Ram Peddi, M.D.<sup>1</sup>;* (1)California Pacific Medical Center, San Francisco, CA; (2)Novartis Pharmaceutical Corporation, East Hanover, NJ

**269F. Cardiovascular Events and CV-Related Mortality After Renal Transplantation: Effect of Maintenance Steroid Therapy and Preexisting Coronary Artery Disease.**

*Adele R. Shields, Pharm.D.,<sup>1</sup> Nicole M. Schmidt, Pharm.D.,<sup>1</sup> Rita R. Alloway, Pharm.D.,<sup>1</sup> Michael Cardi, M.D.,<sup>2</sup> Amit Govil, M.D.,<sup>3</sup> Dennis Hanseman, M.S.,<sup>1</sup> E. Steve Woodle, M.D.<sup>1</sup>;* (1)University of Cincinnati, Cincinnati, OH; (2)The Christ Hospital, Cincinnati, OH; (3)The Health Alliance, Cincinnati, OH

**Best Paper Judging Committee:**

Mary Hayney, Chair  
Gilbert Burckart  
M. Lynn Crismon  
Joseph DiPiro  
Sarah Spinler